Effectiveness and safety of Chinese herbal footbaths as an adjuvant therapy for dysmenorrhea: a systematic review and meta-analysis.

This meta-analysis were implemented following the guidelines of Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and using the RevMan software (Version 5.3; the Cochrane Collaboration, NCC, CPH, Denmark). Additionally, the protocol was registered and published on PROSPERO (PROSPERO CRD 42020188256) ( Xiao et al., 2021 ). Two independent reviewers (JWW and YX) systematically searched ten electronic databases, including the Web of Science, CIHAHL, PubMed, EMBASE, Cochrane Library, China Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang Database, and the Chinese Biomedical Literature Service System (SinoMed), up to June 2023 without any language restriction to identify eligible studies. Search terms were used in a combination as follows: dysmenorrhea, menstrual pain, painful menstruation, period pain, painful period, menstrual cramps, menstrual disorder, pelvic pain, menstrual cramps, painful menstrual periods, Chinese herbal footbaths, bath, hydrotherapy, herbal bathing, lavipeditum, randomized controlled trial, randomized, randomly, trials, and RCT. Manual searches of reference from retrieved articles were also performed. Discrepancies between reviewers were resolved through consultation with a third reviewer. The search strategy used for PubMed is detailed in Table 1 and underwent necessary adjustments to accommodate the requirements of other databases. Search strategy for the PubMed. * Represent one or more characters of all characters. The inclusion criteria, based on the PICOS (patients, intervention, comparator, outcomes, and study design) framework, were pre-specified as: 1) Participants: patients diagnosed with dysmenorrhea of any age, case source, and disease duration and severity; 2) Intervention: CHF, alone or with other treatments; 3) Comparators: basic or conventional medications, other TCM modalities, placebos, or non-intervention; 4) Outcome measurements: primary outcomes of pain relief measured by total effective rate, and secondary outcomes included pain intensity evaluated by validated scales, such as the visual analog scale (VAS) pain intensity score and the Cox menstrual symptom scale (CMSS) score symptom score, TCM syndrome scale, and adverse events; and 5) Types of study: only RCTs published in a peer-reviewed journal were included. Exclusion criteria filtered out studies were: 1) of non-RCT, animal studies, case reports, conference proceedings, or literature reviews; 2) with ambiguous diagnostics; 3) of incomplete data or unavailable full-text; or 4) of duplicates. Two independent reviewers (YX and JWW) extracted following data, such as the first author’s name, year of publication, study design, participants characteristics, specifics of CHF and control intervention, and outcomes metrics. Disputes were resolved by a third reviewer (YHC). All data underwent cross-checking before input into the RevMan software (V.5.3). Methodological quality of the included studies was rated by two reviewers independently (YX and YHC) with the Cochrane collaboration risk assessment tool. The risk of bias was evaluated across the following domains and classified as high, unclear, or low: 1) random sequence generation; 2) allocation concealment; 3) blinding of participants and personnel; 4) blinding of outcome assessors; 5) incomplete outcome data; 6) selective reporting; and 7) other bias. Any inconsistency was addressed by consulting a third reviewer (YHC). The quantitative synthesis was performed using RevMan software (v5.3). Risk ratio (RR) was used for dichotomous data and standard mean difference (SMD) or mean difference (MD) for continuous outcomes, each with 95% confidence intervals (CIs). Heterogeneity was measured using the Q-test and I 2 statistic, with a random-effects model applied for substantially heterogeneity ( I 2 ≥ 50%) and a fixed-effects model otherwise. Publication bias was examined using funnel plots, and the robustness and reliability of the findings was tested with the sensitivity analysis by removing individual studies from the pooled data. A P -value less than 0.05 was considered statistically significant.

Initially, 240 studies investigating CHF’s effectiveness and safety in dysmenorrhea treatment were retrieved. After eliminating 64 duplicated entries, the abstract and titles of remaining studies were screened to remove another 138 studies. A thorough review of the full text of the remaining 38 documents led to a further exclusion of 20 research due to the following reasons: one study with unrelated objective, 18 lack of control groups, and one duplication. Ultimately, 18 RCTs were included in the meta-analysis ( Zhang, 2003 ; Qu, 2012 ; Qu and Li, 2012 ; Lei and Liu, 2013 ; Lei and Liu, 2014 ; Ye and Xing, 2017a ; Ye and Xing, 2017b ; Zhang, 2017 ; Liu et al., 2018 ; Yang, 2018 ; Yu and Lu, 2018 ; Yuan et al., 2018 ; Zhang, 2018 ; Zheng et al., 2019 ; Zheng and Li, 2019 ; Zheng, 2020a ; Zheng, 2020b ; Zheng, 2021 ). The PRISMA flowchart of the selection process is depicted in Figure 1 . PRISMA flowchart for eligible study selection process. This meta-analysis encompassed 18 RCTs with sample sizes ranging from 57 to 150 were fulfilled the pre-specified inclusion criteria, involving 1,484 dysmenorrhea patients. All trials were implemented in China and published in Chinese from 2003 to 2021. Dysmenorrhea type was distinctly identified in all studies, including primary dysmenorrhea in 12 studies ( Zhang, 2003 ; Qu, 2012 ; Qu and Li, 2012 ; Ye and Xing, 2017a ; Zhang, 2017 ; Liu et al., 2018 ; Yang, 2018 ; Yu and Lu, 2018 ; Yuan et al., 2018 ; Zhang, 2018 ; Zheng, 2020a ; Zheng, 2021 ), secondary dysmenorrhea due to adenomyosis in four studies ( Ye and Xing, 2017b ; Zheng et al., 2019 ; Zheng and Li, 2019 ; Zheng, 2020b ), and both primary and secondary dysmenorrhea in two studies ( Lei and Liu, 2013 ; Lei and Liu, 2014 ). All control groups received oral medication, namely, Chinese patent medicine in four studies ( Zhang, 2003 ; Yang, 2018 ; Zheng, 2020a ; Zheng, 2021 ), Chinese herbal decoction in 13 studies ( Qu, 2012 ; Qu and Li, 2012 ; Lei and Liu, 2013 ; Lei and Liu, 2014 ; Ye and Xing, 2017a ; Ye and Xing, 2017b ; Zhang, 2017 ; Liu et al., 2018 ; Yu and Lu, 2018 ; Yuan et al., 2018 ; Zhang, 2018 ; Zheng and Li, 2019 ; Zheng, 2020a ), and conventional medicine (gestrinone) in one study ( Zheng et al., 2019 ). The patients in the trial groups were treated by CHF in combination with the same oral medications as the control group in 16 studies ( Zhang, 2003 ; Qu, 2012 ; Qu and Li, 2012 ; Lei and Liu, 2013 ; Lei and Liu, 2014 ; Ye and Xing, 2017a ; Ye and Xing, 2017b ; Zhang, 2017 ; Liu et al., 2018 ; Yu and Lu, 2018 ; Yuan et al., 2018 ; Zhang, 2018 ; Zheng and Li, 2019 ; Zheng, 2020a ; Zheng, 2020b ; Zheng, 2021 ), with medication different from the control group in one study ( Yang, 2018 ), and alone in one study ( Zheng et al., 2019 ). Regarding outcome measurements, 15 studies reported the total effective rate ( Zhang, 2003 ; Qu, 2012 ; Qu and Li, 2012 ; Lei and Liu, 2013 ; Lei and Liu, 2014 ; Ye and Xing, 2017a ; Zhang, 2017 ; Liu et al., 2018 ; Yang, 2018 ; Yu and Lu, 2018 ; Yuan et al., 2018 ; Zhang, 2018 ; Zheng et al., 2019 ; Zheng, 2021 ), two studies exhibited the VAS ( Zhang, 2018 ; Zheng et al., 2019 ), one study presented the CMSS ( Zheng and Li, 2019 ), five studies noted symptom score ( Lei and Liu, 2013 ; Yuan et al., 2018 ; Zhang, 2018 ; Zheng et al., 2019 ; Zheng, 2021 ), and four trials provided TCM syndrome scale ( Qu, 2012 ; Zhang, 2018 ; Zheng, 2020a ; Zheng, 2020b ). The basic characteristics of the included trials are summarized in Table 2 , the information of CHF formulas, preparation, and interventional details is presented in Table 3 , and the detailed information of those highly-frequent used Chinese herbs (n > 5) is presented in Table 4 . Characteristics of the included RCTs in this study. T., treatment group; C., control group; *month; NA, not available; PD, primary dysmenorrhea; SD, secondary dysmenorrhea; HJXJ, capsule, HongJin XiaoJie capsules; ZYXZ, decoction, ZhuYang XiaoZhen decoction; GXZY, decoction, GeXia ZhuYu decoction; LGDS, decocotion, LingGui DanShen decoction; ZYXZ, decoction, ZhuYang XiaoZhen decoction; SFZY, decoction, ShaoFu ZhuYu decoction; SFZY, pill, ShaoFu ZhuYu pill; WYSHZY, decoction, WenYang SanHan ZhuYu decoction; ZYTJ, decoction, ZhuYang TiaoJing decoction; WJ, decoction, WenJing decoction; CMSS, the Cox menstrual symptom scale; VAS, visual analogu sacle. Information of CHF formulas(g), intervention parameters, and TCM pattern differentiation. Information of Chinese herbs that highly-frequent used to relieve dysmenorrhea in the 18 CHF prescriptions included by this study (n ≥ 5 times). As shown in Figure 2 , the methodological quality of the included studies was relatively low. All included studies claimed to be randomized, and one described the randomization method ( Zheng, 2020a ). Due to the inherent nature of the interventions, participant blinding was unfeasible in these studies, and none of them clarified their blinding procedures. All the studies mentioned but did not detail the process of allocation concealment or outcome assessment. Each study presented complete data. The risks of selective reporting and other biases were remained unclear due to insufficient information. The detailed results are presented in Figure 2 . Assessment of methodological quality by the Cochrane risk-of-bias tool. Sixteen studies ( Zhang, 2003 ; Qu, 2012 ; Qu and Li, 2012 ; Lei and Liu, 2013 ; Lei and Liu, 2014 ; Ye and Xing, 2017a ; Ye and Xing, 2017b ; Zhang, 2017 ; Liu et al., 2018 ; Yang, 2018 ; Yu and Lu, 2018 ; Yuan et al., 2018 ; Zhang, 2018 ; Zheng et al., 2019 ; Zheng and Li, 2019 ; Zheng, 2020b ) reported the total effective rate, and a fixed-effect model was utilized due to mild heterogeneity across studies ( I 2 = 0%). The meta-analysis of the pooled data demonstrated that CHF as an adjuvant therapy yielded a statistically significant improvement in the total effective rate (RR 1.18, 95% CI: 1.12 to 1.23, P < 0.00001) ( Figure 3 ). Forest plot for the total effective rate of adjunctive CHF therapy versus control group. CHF, Chinese herbal footbaths. Further subgroup analyses were conducted based on different dysmenorrhea types and TCM patterns, revealing a significant improvement in the total effective rates in 11 trials ( Zhang, 2003 ; Qu, 2012 ; Qu and Li, 2012 ; Ye and Xing, 2017b ; Zhang, 2017 ; Liu et al., 2018 ; Yang, 2018 ; Yu and Lu, 2018 ; Yuan et al., 2018 ; Zhang, 2018 ; Zheng, 2020a ) of primary dysmenorrhea (RR 1.15, 95% CI: 1.09 to 1.21, P < 0.00001), three trials ( Ye and Xing, 2017a ; Zheng et al., 2019 ; Zheng and Li, 2019 ) of secondary dysmenorrhea (RR 1.21, 95% CI: 1.09 to 1.33, P < 0.00001) ( Figure 4 ), as well as two trials ( Yuan et al., 2018 ; Zheng, 2020b ) of TCM patterns of qi stagnation and blood stasis (RR 1.24, 95% CI: 1.05 to 1.47, P < 0.01), two trials ( Ye and Xing, 2017b ; Zheng and Li, 2019 ) of yang deficiency and cold coagulation (RR 1.18, 95% CI: 1.05 to 1.33, P < 0.01), and eight trials ( Qu, 2012 ; Qu and Li, 2012 ; Lei and Liu, 2013 ; Lei and Liu, 2014 ; Zhang, 2017 ; Liu et al., 2018 ; Yang, 2018 ; Zhang, 2018 ; Zheng et al., 2019 ) of cold coagulation and blood stasis (RR 1.19, 95% CI: 1.11 to 1.27, P < 0.00001). A moderate improvement was also noted for cold-dampness coagulation pattern, but without statistical significance (RR 1.08, 95% CI: 0.86 to 1.36, P = 0.49, I 2 = Not applicable) ( Figure 5 ). Forest plot for the total effective rate of adjunctive CHF therapy versus control group in terms of PD and SD. PD, Primary dysmenorrhea. SD, Secondary dysmenorrhea. Forest plot for the total effective rate of adjunctive CHF therapy versus control group in terms of different TCM Patterns. Two studies ( Zhang, 2018 ; Zheng et al., 2019 ) reported the VAS, and a fixed-effect model was adopted due to the mild heterogeneity ( I 2 = 1%). The aggravated effect of meta-analysis showed that CHF adjunctive intervention led to a significant decline in the VAS (MD 0.88, 95% CI: 0.68 to 1.09, P < 0.00001) ( Supplementary Figure S1 ). Another study ( Zheng and Li, 2019 ) reported a substantial reduction in the CMSS (MD 3.61, 95% CI: 2.73 to 4.49, P < 0.00001) in the CHF trial group as compared to the control group ( Supplementary Figure S2 ). Five studies ( Lei and Liu, 2014 ; Yuan et al., 2018 ; Zhang, 2018 ; Zheng et al., 2019 ; Zheng, 2020a ) assessed the symptom score, and a random-effect model was applied due to the significant heterogeneity ( I 2 = 74%). The meta-analysis of pooled data demonstrated that compared to the control group, CHF as an adjunctive intervention markedly reduced the symptom score (SMD 1.09, 95% CI: 0.64 to 1.53, P < 0.00001) ( Figure 6 ). Forest plot for symptom score of adjunctive CHF therapy versus control group. Further subgroup analyses based on different dysmenorrhea types demonstrated that a significant reduction in the symptom score in three trials ( Yuan et al., 2018 ; Zhang, 2018 ; Zheng, 2020b ) with primary dysmenorrhea (SMD 1.31, 95% CI: 0.62 to 2.00, P < 0.001) and one trial ( Zheng et al., 2019 ) with secondary dysmenorrhea due to adenomyopathy (SMD 1.09, 95% CI: 0.70 to 1.47, P < 0.00001) ( Figure 7 ). Forest plot for symptom score of CHF subgroup analysis on primary and secondary dysmenorrhea. CHF, Chinese herbal footbaths. Five studies ( Qu, 2012 ; Zhang, 2018 ; Zheng and Li, 2019 ; Zheng, 2020a ; Zheng, 2021 ) evaluated the TCM syndrome scale, and a random-effect model was utilized due to pronounced heterogeneity ( I 2 = 88%). The meta-analysis unveiled that CHF application substantially improved the TCM syndrome scale compared to the control group (MD 3.76, 95% CI: 2.53 to 4.99, P  < 0.0001) ( Figure 8 ). Forest plot for TCM syndrome scale of adjunctive CHF therapy versus control group. TCM, traditional Chinese medicine; CHF, Chinese herbal footbaths. Further subgroup analyses based on different dysmenorrhea types and TCM patterns demonstrated that a significant decrease in the TCM syndrome score in four trials ( Qu, 2012 ; Zhang, 2018 ; Zheng, 2020b ; Zheng, 2021 ) of primary dysmenorrhea (MD 3.02, 95% CI: 2.66 to 3.38, P < 0.00001), one trial ( Zheng and Li, 2019 ) of secondary dysmenorrhea (MD 5.21, 95% CI: 4.52 to 5.90, P < 0.00001) ( Figure 9 ), as well as one trial ( Zheng, 2021 ) of TCM pattern of qi stagnation and blood stasis in (SMD 0.95, 95% CI: 0.41 to 1.48, P < 0.001), two trials ( Zheng and Li, 2019 ; Zheng, 2020a ) of yang deficiency and cold coagulation (SMD 3.10, 95% CI: 2.64 to 3.56, P < 0.00001), and two trials ( Qu, 2012 ; Zhang, 2018 ) of cold coagulation and blood stasis (SMD 1.02, 95% CI: 0.66 to 1.38, P < 0.00001) ( Figure 10 ). Forest plot for TCM syndrome scale of CHF subgroup analysis on primary and secondary dysmenorrhea. Forest plot for TCM syndrome scale of CHF subgroup analysis on different TCM patterns. Four studies ( Qu and Li, 2012 ; Lei and Liu, 2013 ; Ye and Xing, 2017a ; Ye and Xing, 2017b ) addressed the concern of adverse events, and two of which ( Lei and Liu, 2013 ; Ye and Xing, 2017a ) assessed the safety with blood, urine, and stool routine tests, as well as hepatic and renal function assessments. No adverse events were recorded in the CHF adjunctive treatment group. Five studies ( Qu, 2012 ; Liu et al., 2018 ; Yang, 2018 ; Yuan et al., 2018 ; Zheng, 2020b ) reported follow-up data over a 3-month span. Narratively, the CHF adjunctive treatment presented an optimal sustainable therapeutic benefit, as evident by the enhanced total effective rate (RR 1.34, 95% CI: 1.11 to 1.63, P < 0.01) in two trials ( Yuan et al., 2018 ; Zheng, 2020a ) and a diminished recurrence rate (RR 0.19, 95% CI: 0.09 to 0.39, P < 0.0001) in three trials ( Qu, 2012 ; Liu et al., 2018 ; Yang, 2018 ) when compared with the control group ( Supplementary Figures S3, S4 ). Funnel plots were employed to evaluate the potential publication bias. The resultant plots for the total effective rate demonstrated an asymmetric distribution, suggesting a possibility of publication bias ( Supplementary Figure S5 ). However, this potentiality was offset by the value of Egger’s test ( P > 0.05), indicating the likelihood of publication bias was not evident. Sensitivity analyses were conducted for the total effective rate, VAS, and TCM syndrome scale. The results revealed that excluding any individual study from each outcome did not significantly alter the aggravated effect, indicating the stability and robustness of the pooled results.

In conclusion, this study suggests that Chinese herbal footbaths may serve as a promising and safe adjuvant therapy for dysmenorrhea management. However, the limited data and variable methodological quality of the included studies necessitate a cautious interpretation of these findings. Further verification with more well-designed high-quality multicenter RCTs of large sample size are warranted.

Dysmenorrhea remains a predominant public health concern that impairs women’s quality of life, academic performance, and work productivity. Despite considerable research efforts, its complex pathomechanisms underlying are not yet fully deciphered. Beyond conventional pharmacological solutions, the medical community has gradually well-recognized the importance and promise of complementary and alternative interventions ( Sosorburam et al., 2019 ; Su et al., 2021 ). Previous studies indicate the potential benefits of CHF in mitigating dysmenorrhea, yet comprehensive evidence remains limited. To the best of our knowledge, this is the first systematical review and meta-analysis to evaluate the effectiveness and safety of CHF as an adjunctive therapy for the management of dysmenorrhea. The findings of the present meta-analysis suggested that CHF therapy could significantly enhance the total effective rate and reduce the VAS, CMSS, symptom score and TCM syndrome scale, consolidating its potential as an effective adjunctive intervention for patients suffered from dysmenorrhea. Furthermore, it displayed fewer adverse events and optimal sustainable long-term therapeutic benefits. The desirable clinical outcomes of CHF on dysmenorrhea are attributable to multi-factors. In the TCM paradigm, the feet are corresponded to different internal organs and regions of human body via specific channels and acupuncture points, and the absorption of Chinese herbs through skin and mucosa may act on these channels and acupuncture points, potentially alleviating visceral pain ( Matos et al., 2021 ). Moreover, the thermal effect of footbaths may improve microcirculation and skin permeability, facilitating the assimilation of the active ingredients in the herbal concoctions ( Zheng et al., 2019 ; Fu et al., 2020 ). Moreover, the results of subgroup analysis based on different dysmenorrhea types and TCM patterns showed that CHF yielded a significant improvement in the total effective rate, symptom scores, and TCM syndrome scale for patients with either primary or secondary dysmenorrhea associated with qi stagnation and blood stasis, yang deficiency and cold coagulation, or cold coagulation and blood stasis. In the therapeutic framework of TCM, pattern differentiation serves as the foundation for the therapeutic interventions ( Zheng, 2020b ; Li X. et al., 2023 ). Dysmenorrhea is generally divided into two pathological categories, namely, Excesses of “pain due to obstruction” and Deficiency of “pain due to lack of nourishment.” The former is primarily arising from the blockage of qi and blood circulation due to internal and external pathogenic factors, such as cold, dampness, and heat, with cold-induced blockage being most notably prevalent. For relief, patients with “cold womb” are advised to expel cold and remove qi stagnation and blood stasis to relieve pain. While the latter is often caused by deficiency of Qi, blood, yin or yang, necessitating a focus on tonification and replenishment to address the deficiencies and nourish the “withered womb” ( Sosorburam et al., 2019 ; Dong et al., 2022 ; Wu L.-J. et al., 2023 ). This meta-analysis incorporating 1,484 dysmenorrhea patients, either primary or secondary, identified cold coagulation, blood stasis, qi stagnation, and yang deficiency as prevalent etiopathogenesis. Accordingly, such well-recognized Chinese herbal prescriptions as WenJing Tang and Shaofu Zhuyu Tang are recommended for CHF to ensure the optimal clinical outcomes, as specified in Tables 2 , 3 . This also underscores the critical role of accurate pattern differentiation for CHF to achieve significant improvements in managing dysmenorrhea. In addition, current insight into dysmenorrhea underscores its complex etiopathogenesis involving multiple factors, such as vasopressin, oxytocin, calcium, oxidative stress, inflammation, and nitric oxide, with prostaglandins (PGs), synthesized from arachidonic acid via the cyclooxygenase (COX) pathway, playing a pivotal role ( Jabbour et al., 2006 ; Tu and Hellman, 2021 ; Snipe et al., 2024 ; Xiao et al., 2024 ). A further analysis demonstrates that 51 different Chinese herbs were employed in the 18 CHF prescriptions for dysmenorrhea in this meta-analysis, and 17 of which were identified as frequently used ingredients (frequency≥5 times), such as Chuanxiong Rhizoma ( Ligusticum chuanxiong Hort ) (n = 14), Angelicae Sinensis Radix [Dang Gui (Angelica sinensis (Oliv.) Diels) (n = 14), Euodiae Fructus [ Euodia rutaecarpa (Juss.) Benth ] (n = 13), Corydalis Rhizoma ( Corydalis yanhusuo W.T. Wang ) (n = 11), Paeoniae Radix Rubra ( Paeonia lactiflora Pall. ) (n = 8), Cinnamomi Ramulus [Cinnamomum cassia (L.) J. Presl] (n = 8), and Spatholobi Caulis ( Spatholobus suberectus Dunn ) (n = 8). These herbs are well-recognized for their pharmacologic effects of analgesia, spasmolysis, microcirculation, anti-inflammation, vasodilatation, and neuroprotection, as documented in Table 4 . Experiments have also indicated the mechanism underlying their therapeutic effects on dysmenorrhea may attribute to modulate oestradiol, arginine vasopression, oxytocin and its receptor, PGE 2 and PGF 2α expression; inhibit calcium channel, nuclear factor-κB(NF-κB), NF-κB/p38, mitogenactivated protein kinase, and COX-2; elevate nitric oxide and its synthetase; downregulate oxytocin, vasopressin, endothelin-1, malondialdehyde, superoxide, interleukin-6 (IL-6), IL-1β, monocyte chemotactic protein 1, inducible nitric oxide synthase, tumor necrosis factor-2α, whole blood viscosity, and plasma viscosity ( Zhang et al., 2016 ; Sosorburam et al., 2019 ; Shao et al., 2020 ; Tan et al., 2020 ; Liu et al., 2021a ; Dong et al., 2022 ; Mo et al., 2022 ; Wu T. et al., 2023 ; Cai and Feng, 2023 ; Li M. et al., 2024 ). Although this meta-analysis assessed the effectiveness and safety of CHF as a supplementary treatment for dysmenorrhea, there are several limitations: 1) the small sample size of some studies might overrate the perceived effectiveness and undermine outcome reliability; 2) the inherent characteristics of CHF made blinding and allocation concealment unfeasible, potentially resulting in overestimated therapeutic benefits; 3) notable heterogeneity was presented in the aggravated results of symptom score and TCM syndrome scale, which might attribute to diverse efficacy criteria, differences in CHF formulation, and inconsistencies in treatment durations, temperatures, and immersion depths across studies. However, subgroup analysis was infeasible due to the limited number of studies, potentially compromising result accuracy and applicability; 4) the methodological quality of some studies was suboptimal and might cause an overestimated therapeutic effect; and 5) despite no language limitation for inclusion, all sourced publication were in Chinese, and the funnel plot implied the slight possibility of publication bias. Given these limitations, more well-designed, high-quality, large-sample sized RCTs are warranted to consolidate confidence in the therapeutic benefits of CHF for dysmenorrhea. Future research should also aim to evaluate the holistic impact of CHF on dysmenorrhea patients in such variables as over-all quality of life and sleep quantity and quality.

Dysmenorrhea, marked by cramping and pain in the lower abdomen during or before menstruation, remains a prevalent but disregarded, underdiagnosed, and inadequately treated gynecological issue ( Itani et al., 2022 ; MacGregor et al., 2023 ). It affects up to 93% of adolescents and an estimated 16%–91% of women of childbearing age ( Ju et al., 2014 ; De Sanctis et al., 2015 ; Campbell, 2019 ). This ailment, primary or secondary, may severely impact patients’ daily activities, leading to reduced academic achievements among teenagers and reduced productivity and work performance for adults ( Tu et al., 2024 ). In the United States, dysmenorrhea is responsible for approximately 600 million hours of work lost with two billion dollars of financial cost annually ( Iacovides et al., 2015 ). The primary pharmacological remedies include non-steroidal-anti-inflammatory drugs and hormonal contraceptives, yet about 15% of patients find no relief with these interventions. Moreover, prolonged use may cause adverse events affecting the gastrointestinal, neurological, and cardiovascular systems ( Oladosu et al., 2018 ; Lopes Dias et al., 2019 ). This situation highlights the necesseity for an increased medical attention and alternative treatment strategies ( Tu and Hellman, 2021 ). Given these challenges, there has been a growing interest in complementary and alternative therapy over recent years, and a substantial number of patients with dysmenorrhea turning to traditional Chinese medicine (TCM) for solution ( Sosorburam et al., 2019 ; Zhang et al., 2024 ). Chinese herbal footbaths (CHF), an ancient TCM modality dating back over three millennia, has been utilized in China to address a broad spectrum of health issues, including menstrual symptoms. In the CHF treament, individuals soak their feet and lower legs in a warm herbal concoction for 20–30 min, benefiting from more than just relaxation. This external therapeutic approach cooperates the soothing heat and reflective effects with the healing properties of specific Chinese herbs, prescribed in accordance with individual-oriented TCM pattern differentiations ( Chen et al., 2019 ; Xiao et al., 2021 ). Despite its longstanding usage, the scientific community recently has conducted an increasing body of randomized controlled trials (RCTs) investigating the effectiveness and safety of CHF for dysmenorrhea management, yet a thorough systematic review and meta-analysis consolidating these findings on the subject remains unreported. Hence, this study aimed to methodically assess the available evidence on the effectiveness and safety of CFH in alleviating dysmenorrhea, yielding potentially valuable information for patients, healthcare providers, and researchers concerned.